T. Rowe Price Associates
ELTX icon

T. Rowe Price Associates’s Elicio Therapeutics ELTX Stock Holding History

T. Rowe Price Associates’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,270
Closed -$124K – 2998
2021
Q3 		$124K Buy
+1,270
New +$137K ﹤0.01% 2803

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's ELTX Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 1,270 shares — an estimated $124K sold.

T. Rowe Price Associates first reported a position in ELTX in Q3 2021 and held it in 1 quarter. The position peaked at $124K in Q3 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,270 Elicio Therapeutics shares in Q4 2021, an estimated $124K.
  • T. Rowe Price Associates first reported a position in Elicio Therapeutics in Q3 2021 and held it in 1 quarter.
  • T. Rowe Price Associates's Elicio Therapeutics position peaked at $124K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.